218 related articles for article (PubMed ID: 2212951)
1. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.
Gansbacher B; Zier K; Daniels B; Cronin K; Bannerji R; Gilboa E
J Exp Med; 1990 Oct; 172(4):1217-24. PubMed ID: 2212951
[TBL] [Abstract][Full Text] [Related]
2. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.
Gansbacher B; Bannerji R; Daniels B; Zier K; Cronin K; Gilboa E
Cancer Res; 1990 Dec; 50(24):7820-5. PubMed ID: 2123742
[TBL] [Abstract][Full Text] [Related]
3. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
Ley V; Langlade-Demoyen P; Kourilsky P; Larsson-Sciard EL
Eur J Immunol; 1991 Mar; 21(3):851-4. PubMed ID: 2009918
[TBL] [Abstract][Full Text] [Related]
5. Induction of tumor-specific cytotoxic T lymphocytes and natural killer cells by tumor cells transfected with the interleukin-2 gene.
Iwanuma Y; Kato K; Yagita H; Okumura K
Cancer Immunol Immunother; 1995 Jan; 40(1):17-23. PubMed ID: 7828164
[TBL] [Abstract][Full Text] [Related]
6. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
7. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts.
Tsai SC; Gansbacher B; Tait L; Miller FR; Heppner GH
J Natl Cancer Inst; 1993 Apr; 85(7):546-53. PubMed ID: 8455201
[TBL] [Abstract][Full Text] [Related]
8. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
9. The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer.
Leong CC; Marley JV; Loh S; Robinson BW; Garlepp MJ
Immunol Cell Biol; 1997 Aug; 75(4):356-9. PubMed ID: 9315477
[TBL] [Abstract][Full Text] [Related]
10. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice.
Haddada H; Ragot T; Cordier L; Duffour MT; Perricaudet M
Hum Gene Ther; 1993 Dec; 4(6):703-11. PubMed ID: 8186285
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism.
Pulaski BA; McAdam AJ; Hutter EK; Biggar S; Lord EM; Frelinger JG
Cancer Res; 1993 May; 53(9):2112-7. PubMed ID: 8097675
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness.
Zier KS; Salvadori S; Cronin KC; Gansbacher B
Cancer Gene Ther; 1994 Mar; 1(1):43-50. PubMed ID: 7621237
[TBL] [Abstract][Full Text] [Related]
14. Retroviral-mediated IL-2 gene transfer into murine neuroblastoma.
Cho HS; Song JY; Park CY; Lyu CJ; Kim BS; Kim KY
Yonsei Med J; 2000 Feb; 41(1):76-81. PubMed ID: 10731923
[TBL] [Abstract][Full Text] [Related]
15. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells.
Porgador A; Gansbacher B; Bannerji R; Tzehoval E; Gilboa E; Feldman M; Eisenbach L
Int J Cancer; 1993 Feb; 53(3):471-7. PubMed ID: 8428800
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
Provinciali M; Argentati K; Tibaldi A
Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
[TBL] [Abstract][Full Text] [Related]
17. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
19. Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN-gamma [corrected] elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
Qi Y; Chen Y; Xiang J
J Interferon Cytokine Res; 1996 Oct; 16(10):771-6. PubMed ID: 8910761
[TBL] [Abstract][Full Text] [Related]
20. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer.
Suzuki K; Nakazato H; Matsui H; Hasumi M; Shibata Y; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
J Leukoc Biol; 2001 Apr; 69(4):531-7. PubMed ID: 11310838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
